KIT and PDGFRA Variants and the Survival of Patients with Gastrointestinal Stromal Tumor Treated with Adjuvant Imatinib

Key Points

Key points are not available for this paper at this time.

Abstract

mutations. Adjuvant imatinib improves OS substantially if high-risk GISTs can be identified, treatment duration is long enough, and GISTs harbor an imatinib-sensitive mutation.

Bookmark

View Full Paper

Cite This Study

Heikki Joensuu (Sun,) studied this question.

synapsesocial.com/papers/6a078712beabdc12ba079c56 https://doi.org/https://doi.org/10.3390/cancers15153879

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas2015 · 172 citations
2One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor2012 · 968 citations
3Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up2021 · 559 citations
4Medical oncological treatment for patients with Gastrointestinal Stromal Tumor (GIST) – A systematic review2022 · 15 citations
5Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up2018 · 751 citations

Bookmark

View Full Paper